Intel (INTC) stock sank 1.45% even though analysts told Reuters that the ... after achieving the first development milestone under its strategic …
GlaxoSmithKline (GSK) popped to an 11-month high Thursday after its two-drug HIV treatment proved non-inferior to a three-drug regimen using …
StockMarketWire.com - GlaxoSmithKline said Thursday that its two-drug treatment for HIV, met its primary goal after demonstrating the ability to control HIV. The studies met their primary endpoint for non-inferiority, a standard measure of HIV control ...
Shares of Mylan N.V. (MYL - Free Report) are down after the company announced that the FDA will not approve its Abbreviated New Drug Application for the generic version of GlaxoSmithKline ... Mylan’s stock has gained …
In other notable single-stock movers, Rolls Royce (RR.L ... The biggest boost to the index was pharmaceutical company GlaxoSmithKline (GSK.L) which gained 0.7 percent after its two-drug treatment for HIV met its main goal in …
Reuters · 7d
(Reuters) - GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field. The combination of dolutegravir and lamivudine was shown to ...
StockMarketWire.com - GlaxoSmithKline said its head of vaccines, Luc Debruyne, would leave the company at the end of the year. He would be replaced in the role on 1 September by Roger Connor, who was currently the company's head of global manufacturing and ...
(Reuters) - GlaxoSmithKline Plc (L:GSK) said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year. Roger Connor, president of its global manufacturing and supply division since 2012, would replace Debruyne on ...